- Citations, last 5 years
- 78
- Works, last 5 years
- 11
- h-index
- 26
- Scientists listed
- 3
- Grants since 2016
- 60
Grants received
2025–2027 · research · R44
Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma
Colleen Doyle Cooper · Celdara Medical (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke
Julie H Coleman · Celdara Medical (United States) · funded by National Institutes of Health
2023–2024 · research · R44
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2023–2026 · research · R43
Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke
Julie H Coleman · Celdara Medical (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2022–2023 · research · R44
Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas
Colleen Doyle Cooper · Celdara Medical (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Preclinical development of an important, broad-spectrum antibody for pandemic influenza
Colleen Doyle Cooper · Celdara Medical (United States) · funded by National Institutes of Health
2022–2023 · research · R43
CAR T platform to treat solid tumors
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2022–2023 · research · R44
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2022–2027 · research · R25
Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF)
Julie H Coleman · Celdara Medical (United States) · funded by National Institutes of Health
2022–2027 · research · R25
Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF)
Julie H Coleman · Celdara Medical (United States) · funded by National Institutes of Health
2022–2027 · research · R25
Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF)
Julie H Coleman · Celdara Medical (United States) · funded by National Institutes of Health
2022–2026 · research · R44
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2022–2024 · research · R43
Development of a broad spectrum antimicrobial to combat chronic lung infection
Colleen Doyle Cooper · Celdara Medical (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2022–2026 · research · R44
Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas
Colleen Doyle Cooper · Celdara Medical (United States) · funded by National Institutes of Health
2022–2027 · research · R25
Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF)
Julie H Coleman · Celdara Medical (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2021–2022 · research · R41
A Novel Broad-spectrum Antiviral Agent
Jason W. Botten · Celdara Medical (United States) · funded by National Institutes of Health
2021–2022 · research · R44
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2021–2022 · research · R41
A Novel Broad-spectrum Antiviral Agent
Jason W. Botten · Celdara Medical (United States) · funded by National Institutes of Health
2021–2025 · research · R44
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2020–2022 · contract · N43
SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Biomarker of IAPP dysfunction in prediabetes and early type 2 diabetes mellitus (T2DM)
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2020–2022 · research · R41
Autonomous RNA-Mediated Anti-Influenza A Virus Therapeutics (AMRed Therapeutics)
Brandy Lynn Houser · Celdara Medical (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Antimicrobial peptides to combat MDR ESKAPE pathogens
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2019–2022 · research · R43
A novel antibody therapy for Sin Nombre virus infection
Joana M Murad · Celdara Medical (United States) · funded by National Institutes of Health
2019–2022 · research · R44
Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM
Brandy Lynn Houser · Celdara Medical (United States) · funded by National Institutes of Health
2019–2020 · research · R43
A novel antibody therapy for Sin Nombre virus infection
Michael W Fanger · Celdara Medical (United States) · funded by National Institutes of Health
2019–2021 · contract · N43
DISCOVERY OF PARASITE-DERIVED TOLEROGENIC ADJUVANTS
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2019–2023 · research · R44
Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM
Jake Reder · Celdara Medical (United States) · funded by National Institutes of Health
2019–2020 · research · R44
Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM
Michael W Fanger · Celdara Medical (United States) · funded by National Institutes of Health
2018–2023 · research · R44
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2018–2021 · cooperative agreement · UT2
DRIVEN: Accelerating Medical Entrepreneurship in the Northeast
Jake Reder · Celdara Medical (United States) · funded by National Institutes of Health
2018–2019 · cooperative agreement · UT2
DRIVEN: Accelerating Medical Entrepreneurship in the Northeast
Jake Reder · Celdara Medical (United States) · funded by National Institutes of Health
2018–2020 · contract · N01
Discovery of novel helminth immunomodulatory proteins for autoimmune diseases
(Contact) · Celdara Medical (United States) · funded by National Institutes of Health
2018–2023 · research · R44
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
Paul Guyre · Celdara Medical (United States) · funded by National Institutes of Health
2018–2022 · cooperative agreement · UT2
DRIVEN: Accelerating Medical Entrepreneurship in the Northeast
Jake Reder · Celdara Medical (United States) · funded by National Institutes of Health
2018–2024 · research · R44
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
Jake Reder · Celdara Medical (United States) · funded by National Institutes of Health
